Calamos Wealth Management LLC Dexcom Inc Transaction History

Calamos Wealth Management LLC

$1.89 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	BUY	$110.31 - $140.45 $165,906 - $211,236	1,504 Added 2.32%	66,323 $7.52 Million
Q1 2024 May 08, 2024	SELL	$114.22 - $140.1 $1.26 Million - $1.54 Million	-10,999 Reduced 14.51%	64,819 $8.99 Million
Q4 2023 Jan 31, 2024	SELL	$75.49 - $124.16 $134,447 - $221,128	-1,781 Reduced 2.3%	75,818 $9.41 Million
Q3 2023 Oct 25, 2023	BUY	$86.06 - $137.93 $1.47 Million - $2.36 Million	17,082 Added 28.23%	77,599 $7.24 Million
Q2 2023 Jul 28, 2023	SELL	$112.47 - $130.98 $96,836 - $112,773	-861 Reduced 1.4%	60,517 $7.78 Million
Q1 2023 May 03, 2023	SELL	$104.0 - $122.92 $203,320 - $240,308	-1,955 Reduced 3.09%	61,378 $7.13 Million
Q4 2022 Jan 25, 2023	BUY	$84.98 - $122.67 $53,197 - $76,791	626 Added 1.0%	63,333 $0
Q3 2022 Oct 24, 2022	BUY	$76.35 - $94.18 $1.54 Million - $1.89 Million	20,119 Added 47.24%	62,707 $5.05 Million
Q2 2022 Aug 01, 2022	BUY	$67.99 - $132.89 $2.15 Million - $4.21 Million	31,687 Added 290.68%	42,588 $3.17 Million
Q1 2022 May 03, 2022	BUY	$94.08 - $130.2 $13,359 - $18,488	142 Added 1.32%	10,901 $5.58 Million
Q4 2021 Feb 01, 2022	SELL	$129.87 - $162.82 $24,545 - $30,772	-189 Reduced 1.73%	10,759 $5.78 Million
Q3 2021 Oct 26, 2021	BUY	$106.71 - $143.18 $12,911 - $17,324	121 Added 1.12%	10,948 $5.99 Million
Q2 2021 Jul 22, 2021	SELL	$80.99 - $107.93 $57,178 - $76,198	-706 Reduced 6.12%	10,827 $4.62 Million
Q1 2021 Apr 12, 2021	BUY	$84.79 - $104.74 $901,996 - $1.11 Million	10,638 Added 1188.6%	11,533 $4.15 Million
Q4 2020 Jan 27, 2021	BUY	$78.0 - $104.5 $69,810 - $93,527	895 New	895 $331,000

Others Institutions Holding DXCM

# of Institutions

1,014

Shares Held

351M

Call Options Held

5.51M

Put Options Held

5.6M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Calamos Wealth Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Calamos Wealth Management LLC with notifications on news.

Account